ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 499

High Levels of Mir-451a Differentiate Patients at Risk of Developing RA from Healthy Controls

Klára Prajzlerová1, Veronika Hrušková2, Petra Hánová1, Heřman F Mann1, Karel Pavelka1, Jiří Vencovský3, Ladislav Šenolt1 and Mária Filková1, 1Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 2Institute of Rheumatology and Department of Rheumatology, Faculty of Science, Charles University in Prague, Prague, Czech Republic, 3Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Disease Activity, MicroRNA and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:   Individuals with clinically suspect arthralgia (CSA) with positivity of antibodies to citrullinated protein antigens (ACPA) have articular symptoms without clinical signs of arthritis. CSA patients are considered at high risk for progression to RA. The altered expression of miRNAs contributes to the development and maintenance of autoimmune diseases. Moreover, miRNAs appear promising diagnostic and/or prognostic biomarkers. We aimed to investigate differentially expressed peripheral blood mononuclear cell (PBMC)-contained and cell-free circulating miRNAs in CSA and healthy controls (HC).

Methods: The study included 19 CSA individuals and 23 HC. Clinical disease activity assessments (DAS28, SDAI) and disease activity assessed by patient on VAS were performed. By definition, all patients had swollen joint count 0. Ultrasound (US) of 28 small joints was performed in CSA to evaluate subclinical synovitis. Total RNA from plasma and PBMC was isolated using phenol-chloroform extraction or miRNeasy Mini Kit. A comprehensive analysis of miRNAs was performed using TaqMan® Low Density Array (TLDA) in 5 samples per group. The expression of miR-451a was further validated by single assays and normalized to RNU44 for PBMC or an average of 3 spike-in C. elegans controls for circulating miRNAs. dCt was used for relative quantification.

Results: All CSA patients were ACPA+ with CRP 9.1±19.6 mg/l. 9 CSA patients had no activity on US (grey scale≤1 and power doppler=0). Out of the 380 miRNAs analysed by TLDA, 194 miRNAs were detected in PBMC of CSA and 198 in HC while 125 circulating miRNAs were detected in plasma of CSA and 124 in HC. TLDA analysis revealed 2.43x higher levels of miR-451a in PBMC and 1.55x lower levels of circulating miR-451a in CSA compared to HC. Further validation confirmed 3.19x higher expression of miR-451a in PBMC in CSA compared to HC (p=0.001). These levels in CSA significantly correlated with DAS28(CRP) (r=0.575; p=0.010), SDAI (r=0.676; p=0.004) and VAS (r=0.484; p=0.036), but not with tender joint count (r=0.401; p=0.089), ESR (r=-0.042; p=0.869) or CRP (r=0.238; p=0.328). No difference in expression of circulating miR-451a or association with disease activity was demonstrated. Subclinical activity as per US findings had no effect on the levels of miR-451 in PBMC or plasma. There was no correlation between circulating and PBMC levels of miR-451a (r=0.265; p=0.124)

Conclusion: Although CSA cannot be considered a disease itself, and is rather a clinical suspicion of a disease, high levels of miR-451 in PBMC distinguish these at high risk individuals from HC. Moreover, miR-451 reflects the activity at this pre-clinical phase. Acknowledgement: MHCR 023728 and SVV 260263 projects.


Disclosure: K. Prajzlerová, None; V. Hrušková, None; P. Hánová, None; H. F. Mann, None; K. Pavelka, None; J. Vencovský, None; L. Šenolt, None; M. Filková, None.

To cite this abstract in AMA style:

Prajzlerová K, Hrušková V, Hánová P, Mann HF, Pavelka K, Vencovský J, Šenolt L, Filková M. High Levels of Mir-451a Differentiate Patients at Risk of Developing RA from Healthy Controls [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/high-levels-of-mir-451a-differentiate-patients-at-risk-of-developing-ra-from-healthy-controls/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-levels-of-mir-451a-differentiate-patients-at-risk-of-developing-ra-from-healthy-controls/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology